North America Gene Panel Market Outlook & Forecast 2025-2035
The North America Gene Panel Market is witnessing robust expansion due to rising demand for precision medicine and the increasing incidence of genetic disorders and cancer. Innovative advancements in next-generation sequencing (NGS) and a growing focus on personalized healthcare are further transforming the market dynamics. As healthcare systems prioritize early disease detection and pharmaceutical companies accelerate research in pharmacogenomics, gene panels are being rapidly adopted across clinical and research settings. With a range of panel types—single, small, medium, large, comprehensive, and custom—the market supports diverse applications such as cancer risk assessment, prenatal testing, and pharmacogenomics. Hospitals, diagnostic labs, and direct-to-consumer channels remain important distribution points while regulatory standards and strategic partnerships continue to shape market competition and growth.
Latest Market Dynamics
Key Drivers
- Advancements in next-generation sequencing technology drive faster and more cost-effective gene panel development, as seen in Illumina's 2024 launch of more scalable sequencing platforms.
- Increasing adoption of gene panels for cancer risk assessment, with Thermo Fisher Scientific’s Oncomine solutions gaining wider usage in oncology clinics across North America.
Key Trends
- Rising demand for custom gene panels tailored to rare disease diagnostics, with companies like QIAGEN expanding their product portfolios in 2025.
- Growth in direct-to-consumer genetic testing supported by partnerships—Myriad Genetics announced collaboration with telehealth platforms in early 2025 to enable home-based screening.
Key Opportunities
- Expansion of pharmacogenomics applications as major hospitals adopt QIAGEN and Fulgent Genetics panels for personalized medicine implementation.
- Strategic partnerships between diagnostic labs and biotech firms, exemplified by Invitae’s 2025 alliances with insurance providers, lowering patient costs and enlarging access.
Key Challenges
- Ensuring data privacy and security as patient genome data proliferates; BGI Genomics is investing in advanced encryption and compliance post-2024 regulatory scrutiny.
- Integration gaps in existing healthcare IT systems hinder seamless adoption; Eurofins Scientific is piloting interoperability solutions to bridge these divides across clinical networks.
Key Restraints
- High initial investment for NGS infrastructure and skilled personnel limits entry, impacting smaller research institutions compared to larger players like Roche.
- Regulatory hurdles and variable reimbursement policies remain a bottleneck, with Foundation Medicine reporting delays in wide clinical panel adoption due to payer variability.
North America Gene Panel Market Share by Type, 2025
In 2025, comprehensive gene panels account for the largest market share in North America, reflecting the region’s strong emphasis on broad-spectrum genetic screening. Custom panels are gaining traction as institutions pursue more disease-specific and pharmacogenomic solutions. Adoption of large and medium panels continues to rise in hospitals and research labs targeting multi-gene testing for oncology and rare diseases, while small and single gene panels maintain their presence for targeted diagnostics in outpatient and direct-to-consumer settings.
North America Gene Panel Market Share by Application, 2025
Cancer risk assessment dominates application segments in 2025, primarily due to increased awareness and physician recommendation for hereditary cancer screening. Diagnostic and research uses continue to expand, propelled by ongoing genetic studies and clinical initiatives. Pharmacogenomics emerges as a significant application, driven by advancements in precision medicine and growing insurer reimbursement. Prenatal and carrier screening are also steadily increasing, reflecting wider adoption in women’s health and family planning centers.
North America Gene Panel Market Revenue (2020-2035)
The North America Gene Panel Market has experienced consistent revenue growth, rising from $450 million in 2020 to an estimated $1,010 million in 2025. This trajectory is expected to continue, reaching approximately $2,950 million by 2035. Growth is attributed to increased investment in precision medicine initiatives, expanding clinical validation, and greater public awareness. The decade ahead will likely see substantial market size expansion as innovative product launches, regulatory approvals, and partnerships intensify.
North America Gene Panel Market Year-on-Year Growth (2020-2035)
Year-on-year (YOY) growth rates for the North America Gene Panel Market are projected at an average of 14% over the next decade, with peak increases between 2023 and 2027 due to major product launches and healthcare policy shifts. While growth stabilizes post-2030 as market maturity increases, advances in sequencing and broader payer coverage are expected to keep the market buoyant.
North America Gene Panel Market Share by Region, 2025
The United States leads the North America Gene Panel Market, commanding nearly three-quarters of the total share in 2025 due to well-established healthcare infrastructure and a high concentration of biotech firms. Canada’s market share continues to expand on the back of government funding and organization-led innovation. Mexico is seeing slower, steady growth as adoption increases in both public and private sector hospitals.
North America Gene Panel Market Share by Key Players, 2025
In 2025, Illumina retains its position as the market leader, driven by constant technological upgrades and broad distribution channels. Thermo Fisher Scientific closely follows, benefitting from its strong clinical relationships and comprehensive panel offerings. Companies like QIAGEN and Roche hold significant shares due to continuous innovation, while a diverse group including BGI Genomics, Eurofins Scientific, PerkinElmer, and Myriad Genetics collectively cover the remaining market through niche and specialized offerings.
North America Gene Panel Market Share by Buyers, 2025
Hospitals form the primary buyer segment, leveraging panels in diagnostics and personalized treatment planning. Diagnostic laboratories also represent a major share, enabled by their central role in high-throughput testing. Direct-to-consumer purchases are increasing as patient awareness grows and regulatory barriers ease. Research institutions and clinics occupy important but secondary positions in 2025’s buyer landscape.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 1010 |
| Regions | US, Canada, Mexico |
| Segments | By Type (Single Gene Panel, Small Panel, Medium Panel, Large Panel, Comprehensive Panel, Custom Panel), By Application (Cancer Risk Assessment, Pharmacogenomics, Diagnostic & Research, Prenatal Testing, Carrier Screening, Others), By Distribution Channels (Hospitals, Clinics, Diagnostic Laboratories, Research Institutions, Direct-to-Consumer, Others), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Sanger Sequencing, Microarray, Hybridization-Based, Others), By Organization Size (Small, Medium, Large) |
| Players | Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, Roche, BGI Genomics, Eurofins Scientific, Foundation Medicine, GENEWIZ, Myriad Genetics, PerkinElmer, Invitae, ArcherDX, CENTOGENE, Fulgent Genetics |
Key Recent Developments
- June 2024: Illumina introduced its NovaSeq X Plus with streamlined workflows for clinical labs focusing on comprehensive and custom panel solutions.
- July 2024: Thermo Fisher Scientific announced a partnership with major North American cancer centers for the deployment of new gene panel-based MRD (minimal residual disease) testing.
- August 2024: Invitae and UnitedHealthcare collaborated to expand affordable access to hereditary cancer gene panels across U.S. hospital networks.
- September 2024: QIAGEN launched an updated custom gene panel builder specifically for rare neurological disorders in collaboration with Canadian research institutes.
- October 2024: BGI Genomics achieved ISO/IEC 27001 certification, reinforcing its data security standards and compliance for genomic data in North America.
